Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | January 10, 2026 | January 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,430 |
Reported balance
After 2026-01-10 transaction · row 1
1 source rowRow 1 · 2026-01-10 · Exercise / conversion · Acquired 3,430 · Balance 3,430 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-10 · Exercise / conversion · Disposed 3,430 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2026 Filed Jan 16, 2026 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionRestricted Stock Units · Derivative | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015487 · ownership.xml · derivative · entry 2 Kirk Allan · CIK 0001995409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| January 10, 2026 Filed Jan 16, 2026 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionCommon Stock | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015487 · ownership.xml · nonDerivative · entry 1 Kirk Allan · CIK 0001995409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004914 · ownership.xml · derivative · entry 2 Kirk Allan · CIK 0001995409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: 100% of the total restricted stock units will vest on January 10, 2026. F3 · derivative.expiration_date: 100% of the total restricted stock units will vest on January 10, 2026. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 30,870 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004914 · ownership.xml · derivative · entry 1 Kirk Allan · CIK 0001995409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,870 Underlying: Common Stock · 30,870 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:17 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 150,437 | $1.55 Strike: $1.55 | $233,177.35 |
DisclosureSEC source: 0001209191-23-051456 · doc4.xml · derivative · entry 1 Kirk Allan · CIK 0001995409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 Underlying: Common Stock · 150,437 shares Expires 2033-10-02 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on October 2, 2024 and with respect to 75,218 shares on October 2, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.